Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments (2024 - 2025)

Historic Change in Acquisitions & Divestments for SAB Biotherapeutics (SABS) over the last 2 years, with Q2 2025 value amounting to $5.2 million.

  • SAB Biotherapeutics' Change in Acquisitions & Divestments changed N/A to $5.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year change of. This contributed to the annual value of $25.8 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that SAB Biotherapeutics reported Change in Acquisitions & Divestments of $5.2 million as of Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Change in Acquisitions & Divestments ranged from a high of $10.7 million in Q4 2024 and a low of $3.8 million during Q3 2024